NXTC earnings

Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, 2026 BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026. The Company continues to advance its proposed merger (the "Merger") with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases ("Avere"), which is now supported by approximately $820 million of committed f

BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo